- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 2 - Histology, Targeted Therapy and Surgery
Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.
Dr Langer suggests that historically, there’s been a “monolithic approach” to treating NSCLC. “The histologic distinctions have really come to the forefront now in advanced disease, whereas perhaps 8 to 10 years ago it didn’t really make much of a difference,” he says, “so we are holding our pathologists’ ‘feet to the fire.’”
The panel also discusses targeted therapy and surgery in treatment of NSCLC.
Dr Sugarbaker says surgery is dynamic, noting there are a number of techniques to resect or remove the tumor with technology’s help. “These have significantly reduced the morbidity or the stress and pain for the patient.”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
June 23rd 2025This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
